Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Targeted therapy of meningiomas: establishing the therapeutic role and molecular mechanisms of epigenetic modification in clinically aggressive meningiomas in vivo and in vitro

FY 2020-21

Summary
Meningiomas are most common brain tumour in adults but are severely understudied compared to other tumours. Most meningiomas are benign and can be successfully treated with surgery. However, there are a significant cohort of meningiomas (20-30%) that are clinically aggressive and recur rapidly and repeatedly despite maximal standard of care therapy with surgery and radiation. The genomic changes underlying meningiomas have been well investigated but none have led to the development of any effective therapeutics. Our group has focused on DNA methylation in meningiomas, a reversible epigenetic change to DNA that turns specific genes on and off. We identified specific methylation markers that are predictive of tumour aggressiveness and tumour recurrence. Based on these epigenetic changes, we have identified a panel of pharmacologic compounds that act as specific and non-specific epigenetic modifiers. We isolated and cultured benign and clinically aggressive meningioma cell lines from patients in which to test these compounds for their ability to inhibit tumour cell growth and proliferation. We will perform genomic and epigenomic analysis of these cell lines before and after treatment to assess for drug effects on a molecular level. Compounds that demonstrate inhibition of tumour cell growth and proliferation will be translated into our mice model. As part of this model, we will implant meningioma tumour cells into the mouse cranium and monitor for tumour growth with interval neurological imaging. Once tumours grow to a specific, standardized size, we will treat these mice with the candidate compounds identified above, delivered systemically, and monitor for tumour growth, stability, or shrinkage. We will harvest these tumours for staining and molecular analysis as above. Compounds that demonstrate efficacy and safety have the potential to be translated into future clinical trials, particularly for aggressive, treatment-refractory meningiomas.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
437192
Name
Wang Justin Z
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Targeted therapy of meningiomas: establishing the therapeutic role and molecular mechanisms of epigenetic modification in clinically aggressive meningiomas in vivo and in vitro
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Brain Tumour; Epigenetics; Genetics; Meningioma; Methylation; Molecular Biology; Xenograft
Abstract
Meningiomas are most common brain tumour in adults but are severely understudied compared to other tumours. Most meningiomas are benign and can be successfully treated with surgery. However, there are a significant cohort of meningiomas (20-30%) that are clinically aggressive and recur rapidly and repeatedly despite maximal standard of care therapy with surgery and radiation. The genomic changes underlying meningiomas have been well investigated but none have led to the development of any effective therapeutics. Our group has focused on DNA methylation in meningiomas, a reversible epigenetic change to DNA that turns specific genes on and off. We identified specific methylation markers that are predictive of tumour aggressiveness and tumour recurrence. Based on these epigenetic changes, we have identified a panel of pharmacologic compounds that act as specific and non-specific epigenetic modifiers. We isolated and cultured benign and clinically aggressive meningioma cell lines from patients in which to test these compounds for their ability to inhibit tumour cell growth and proliferation. We will perform genomic and epigenomic analysis of these cell lines before and after treatment to assess for drug effects on a molecular level. Compounds that demonstrate inhibition of tumour cell growth and proliferation will be translated into our mice model. As part of this model, we will implant meningioma tumour cells into the mouse cranium and monitor for tumour growth with interval neurological imaging. Once tumours grow to a specific, standardized size, we will treat these mice with the candidate compounds identified above, delivered systemically, and monitor for tumour growth, stability, or shrinkage. We will harvest these tumours for staining and molecular analysis as above. Compounds that demonstrate efficacy and safety have the potential to be translated into future clinical trials, particularly for aggressive, treatment-refractory meningiomas.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wang, Justin Z
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2020-21) | Canada Spends